Pharma BD Deal Intelligence
Gilead completed its acquisition of privately held Ouro Medicines on June 4, 2026 (announced March 23, 2026), paying $1.675B upfront plus up to $500M in contingent milestones (~$2.175B total) for BCMAxCD3 T-cell engager OM336/gamgertamig, in Phase 1/2 for autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and carrying FDA Fast Track and Orphan Drug designations in both. Under a concurrent collaboration, Lakefront Biotherapeutics (the former Galapagos NV, which rebranded effective May 8, 2026) absorbed Ouro's R&D team and runs the ongoing Phase 1/2 studies; Gilead leads registrational and later-stage development and commercialization ex-Greater China. The two companies split the upfront and milestone payments equally, and Lakefront receives tiered 20-23% royalties on gamgertamig net sales. Registrational studies are expected to begin as early as 2027, extending Gilead's inflammation franchise.